The important thing is that this study analyzed that B.breve in the gut significantly affects the mPFS of NSCLC patients receiving anti‐PD‐1 immunotherapy combined with chemotherapy, and B.breve may be an effective biomarker to predict its clinical benefit. Here, PDCD1 is linked to non-small cell lung carcinoma.